Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer
Thomas Hatschek(Karolinska University Hospital), Jonas Bergh(Karolinska Institutet), Ellinor Elinder(Stockholm South General Hospital), Yvonne Brandberg(Karolinska Institutet), Zakaria Einbeigi(Sahlgrenska University Hospital), Tobias Lekberg(Karolinska University Hospital), Aglaia Schiza(Uppsala University Hospital), Erika Isaksson-Friman(Saint Göran Hospital), Ana Bosch(Memorial Sloan Kettering Cancer Center), Jamila Adra(Sahlgrenska University Hospital), Edward Azavedo(Karolinska Institutet), Lena Carlsson(University of Gothenburg), Susanne Agartz(Karolinska Institutet), Theodoros Foukakis(Karolinska Institutet), Mats Hellström(Karolinska University Hospital), Claudia Maes(Karolinska University Hospital), Henrik Lindman(Uppsala University), Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), Judith Bjöhle(Karolinska University Hospital), Per Grybäck(Karolinska University Hospital), Ioannis Zerdes(Karolinska University Hospital), Gyula Pekár(Skåne University Hospital), Hanna Fredholm(Karolinska University Hospital), Ann Charlotte Dreifaldt(Örebro University Hospital), Johan Hartman(Karolinska University Hospital)
Cited by 58
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k